PROC Procaps Group Corp: Enterprise Value to EBITDA Ratio
This daily price chart for Procaps Group S.A. (PROC) demonstrates a metric at . The business relies on the global contract manufacturing market, remaining vulnerable to polymer prices and GMP compliance. Long-term agreements in Latin America ensure a steady cash flow. Exclusive capsule patents and strict FDA oversight provide high resilience to the company's positions.
Comprehensive metric breakdowns and analytics for procapsgroup.com (PROC)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Procaps Group S.A.|PROC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Procaps|PROC - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Procaps Group Corp|PROC - Company Long-Term Loans and Borrowings|Company Short-Term Debt Procaps|Quick Ratio procapsgroup.com
- financial results and valuation multiples details:
PROC - Net Income|Projected Future Earnings Procaps Group S.A.|PROC - P/E Multiple|Future Price to Earnings Procaps Group S.A.|PROC - Market Cap to Earnings and Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Procaps Group Corp|PROC - Operating income before deduction of amortization|Net earnings per share for the last 12 months Procaps|PROC - Earnings per share for the trailing year|Quarterly EPS earnings growth procapsgroup.com|PROC - Net earnings per share change in current year|Net earnings per share growth forecast for next year Procaps Group S.A.
Fundamental valuation:PROC (Procaps Group SA)
The multiple compares the total enterprise value, including net debt, to operating profit before depreciation and amortization, determining the asset's real price. This indicator serves as the primary coordinate axis for analyzing the company's valuation dynamics and identifying advantageous entry points. Stable demand for the medical innovations of Procaps Group S.A. (PROC) makes the company's EV/EBITDA value on the chart a reliable tool for assessing the business's defensive potential.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|MNKD (MannKind Corp) - Company Value to Operating Income Before Depreciation Ratio|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation PCRX (Pacira Corp)|ARS Pharmaceuticals (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA theravance.com (TBPH)|AQST (Aquestive Therapeutics, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio scPharma (SCPH)|EV/EBITDA Multiple TECX|EV/EBITDA Multiple Tonix Pharmaceuticals Holding (TNXP)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization China SXT Pharmaceuticals, Inc. SXTC|EPRX (Eupraxia Pharmaceuticals, Inc.) - Company Value to Operating Income Before Depreciation Ratio|BHST - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Invizyne Technologies EXOZ|ORMP (oramed.com) - Enterprise Value to EBITDA Ratio|Entera Bio - Business Value to Operating Income Before Depreciation|HYFT (MindWalk Holdings) - EV/EBITDA Multiple|ABVC - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cumberland Pharmaceuticals Inc. (CPIX)|QNTM (Quantum BioPharma Ltd.) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FibroGen Corp FGEN|Telomir Pharmaceuticals Corp (TELO) - Company Value to EBITDA|RANI: Enterprise Value to EBITDA Ratio|SNYR - EV/EBITDA Multiple|rallybio.com (RLYB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio LEXX (Lexaria Bioscience Corp.)|Enterprise Value to EBITDA Ratio PULM|PTHL: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptorum Group Limited (APM)|Total Company Value to Operating Income Before Depreciation Ratio lyratherapeutics.com|Impact BioMedical - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio TNF Pharmaceuticals Inc. (TNFA)|cbdMD Corp - EV/EBITDA Multiple|PRFX - EV/EBITDA Multiple|CYTO (altamiratherapeutics.com) - Enterprise Value to EBITDA Ratio|LIPO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization OptiNose|Pieris Pharmaceuticals Inc - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|QLI (Qilian International Corp) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|tffpharma.com (TFFP) - Company Value to EBITDA
